CoChat

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel

Open access

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Few prognostic models for overall survival (OS) are available for patients with metastatic castration-resistant prostate cancer (mCRPC) treated with recently approved agents. We developed a prognostic index model using readily available clinical and laboratory factors from a phase III trial of abiraterone acetate (hereafter abiraterone) in combination with prednisone in post-docetaxel mCRPC. PATIENTS AND METHODS: Baseline data were available from 762 patients treated with abiraterone-prednisone. Factors were assessed for association with OS through a univariate Cox model and used in a multivariate Cox model with a stepwise procedure to identify those of significance. Data were validated using an independent, external, population-based cohort. RESULTS: Six risk factors individually associated with poor prognosis were included in the final model: lactate dehydrogenase > upper limit of normal (ULN) [hazard ratio (HR) = 2.31], Eastern Cooperative Oncology Group performance status of 2 (HR = 2.19), presence of liver metastases (HR = 2.00), albumin ≤4 g/dl (HR = 1.54), alkaline phosphatase > ULN (HR = 1.38) and time from start of initial androgen-deprivation therapy to start of treatment ≤36 months (HR = 1.30). Patients were categorized into good (n = 369, 46%), intermediate (n = 321, 40%) and poor (n = 107, 13%) prognosis groups based on the number of risk factors and relative HRs. The C-index was 0.70 ± 0.014. The model was validated by the external dataset (n = 286). CONCLUSION: This analysis identified six factors used to model survival in mCRPC and categorized patients into three distinct risk groups. Prognostic stratification with this model could assist clinical practice decisions for follow-up and monitoring, and may aid in clinical trial design. TRIAL REGISTRATION NUMBERS: NCT00638690.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdv594

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Kaplan–Meier curves for overall survival and relative hazard ratio by risk group, as estimated by the stepwise final model for patients treated with abiraterone–prednisone (A and B) and prednisone alone (C and D) and for the independent validation dataset (E and F). CI, confidence interval; OS, overall survival. aVersus patients with good prognosis.
Figure 1. Kaplan–Meier curves for overall survival and relative hazard ratio by risk group, as estimated by the stepwise final model for patients treated with abiraterone–prednisone (A and B) and prednisone alone (C and D) and for the independent validation dataset (E and F). CI, confidence interval; OS, overall survival. aVersus patients with good prognosis.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Cited by

See all 177

Metadata

Authors
Chi, K. N., Kheoh, T., Ryan, C. J., Molina, A., Bellmunt, J., Vogelzang, N. J., Rathkopf, D. E., Fizazi, K., Kantoff, P. W., Li, J., Azad, A. A., Eigl, B. J., Heng, D. Y. C., Joshua, A. M., de Bono, J. S., & Scher, H. I.
Affiliations
  • BC Cancer Agency (CA)
  • University of California, San Francisco (US)
  • Comprehensive Cancer Centers of Nevada (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • Université Paris-Sud (FR)
  • Harvard University (US)
  • University of Calgary (CA)
  • University of Toronto (CA)
Corresponding author
Chi, K.N.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2016-03
Volume
27
Issue
3
Pages
454-460
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2196689106
Cited by
167
References
34
Citations by year
2026: 7 · 2025: 8 · 2024: 11 · 2023: 9 · 2022: 17 · 2021: 21 · 2020: 17 · 2019: 28 · 2018: 18 · 2017: 21 · 2016: 7
FWCI
12.39
Type
journal article
Language
en
Open access
Licence
Locations
  • Annals of Oncology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
  • Amgen
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • GlaxoSmithKline
  • Sanofi
  • Teva Pharmaceutical Industries
  • Celgene
  • Genomic Health
  • Endocyte
  • Exelixis
  • Les Laboratories Pierre Fabre
  • MannKind Corporation
  • Astellas Pharma
  • MorphoSys
  • Bavarian Nordic
  • Genentech
  • Chugai Pharmaceutical
  • Takeda Oncology
  • Foundation Medicine
  • National Cancer Institute (P30CA008748)
  • Janssen Biotech
  • Janssen Pharmaceuticals
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Health Sciences › Medicine › Oncology › Bone health and treatments
  • Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
Keywords
metastatic castration-resistant prostate cancer, abiraterone, overall survival, docetaxel, prednisone, lactate dehydrogenase, performance status, liver metastasis, hypoalbuminemia, alkaline phosphatase, risk stratification
MeSH terms
Abiraterone Acetate, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Double-Blind Method, Humans, Male, Prednisone, Proportional Hazards Models, Disease-Free Survival, Prostatic Neoplasms, Castration-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. https://app.cochat.ai/papers/10.1093/annonc/mdv594
The paper
Chi, K. N., Kheoh, T., Ryan, C. J., Molina, A., Bellmunt, J., Vogelzang, N. J., Rathkopf, D. E., Fizazi, K., Kantoff, P. W., Li, J., Azad, A. A., Eigl, B. J., Heng, D. Y. C., Joshua, A. M., de Bono, J. S., & Scher, H. I. (2016). A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. Annals of Oncology. https://doi.org/10.1093/annonc/mdv594

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.